BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

914 related articles for article (PubMed ID: 26676202)

  • 21. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    Wuntakal R; Seshadri S; Montes A; Lane G
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interval debulking surgery for advanced epithelial ovarian cancer.
    Tangjitgamol S; Manusirivithaya S; Laopaiboon M; Lumbiganon P; Bryant A
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD006014. PubMed ID: 26747297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical cytoreduction for recurrent epithelial ovarian cancer.
    Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
    Morrison J; Thoma C; Goodall RJ; Lyons TJ; Gaitskell K; Wiggans AJ; Bryant A
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007927. PubMed ID: 30321910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
    Kokka F; Bryant A; Brockbank E; Powell M; Oram D
    Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platinum-containing regimens for triple-negative metastatic breast cancer.
    Egger SJ; Chan MMK; Luo Q; Wilcken N
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013750. PubMed ID: 33084020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interval debulking surgery for advanced epithelial ovarian cancer.
    Tangjitgamol S; Manusirivithaya S; Laopaiboon M; Lumbiganon P; Bryant A
    Cochrane Database Syst Rev; 2013 Apr; 4(4):CD006014. PubMed ID: 23633332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphadenectomy for the management of endometrial cancer.
    Frost JA; Webster KE; Bryant A; Morrison J
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD007585. PubMed ID: 26387863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interval debulking surgery for advanced epithelial ovarian cancer.
    Tangjitgamol S; Manusirivithaya S; Laopaiboon M; Lumbiganon P
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006014. PubMed ID: 19370622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interval debulking surgery for advanced epithelial ovarian cancer.
    Tangjitgamol S; Manusirivithaya S; Laopaiboon M; Lumbiganon P
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006014. PubMed ID: 19160263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platinum-containing regimens for metastatic breast cancer.
    Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
    Santos FN; Castria TB; Cruz MR; Riera R
    Sao Paulo Med J; 2016; 134(5):465-466. PubMed ID: 27901246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interval debulking surgery for advanced epithelial ovarian cancer.
    Tangjitgamol S; Manusirivithaya S; Laopaiboon M; Lumbiganon P
    Cochrane Database Syst Rev; 2008 Oct; (4):CD006014. PubMed ID: 18843699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
    Lawrie TA; Rabbie R; Thoma C; Morrison J
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
    Hiu S; Bryant A; Gajjar K; Kunonga PT; Naik R
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD007697. PubMed ID: 36041232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance chemotherapy for ovarian cancer.
    Mei L; Chen H; Wei DM; Fang F; Liu GJ; Xie HY; Wang X; Zou J; Han X; Feng D
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD007414. PubMed ID: 23813336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
    Ngoi NY; Syn NL; Goh RM; Goh BC; Huang RY; Soon YY; James E; Cook A; Clamp A; Tan DS
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD012007. PubMed ID: 35188221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.